Evacetrapib是一種強效且選擇性的 CETP 抑制劑，IC50 為 5.5 nM。

Anacetrapib是一種選擇性 CETP 抑制劑，作用于 rhCETP 和 C13S CETP 突變體的 IC50 分別為 7.9 nM 和 11.8 nM，能夠增加 HDL-C、降低 LDL-C，不影響醛固酮和血壓。

Nicotinyl alcohol是一種吡啶衍生物，具有降膽固醇作用。它通過影響膽固醇代謝來降低血液中的膽固醇水平，可能有助于心血管疾病的預防和治療。

Obicetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors substantially increase the concentration of high-density lipoprotein cholesterol (HDL-C), which may have a possible beneficial effect for cardiovascular disease risk reduction.

CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.

Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.

BMS 795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor with IC50 of 4 nM.

Dalcetrapib is a rhCETP inhibitor with IC50 of 0.2 μM.